# SGLT2 Inhibitors and Effects on Hematopoiesis, Inflammation and Metabolic Markers

> **NCT05408936** · — · ACTIVE_NOT_RECRUITING · sponsor: **University of Patras** · enrollment: 80 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** SGLT2 inhibitor

## Key facts

- **NCT ID:** NCT05408936
- **Lead sponsor:** University of Patras
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-06-03
- **Primary completion:** 2023-12-01
- **Final completion:** 2024-06-01
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2024-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05408936

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05408936, "SGLT2 Inhibitors and Effects on Hematopoiesis, Inflammation and Metabolic Markers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05408936. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*